Logo.png
Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Analysis Demonstrates 22+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
August 13, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Analysis Demonstrates 22+ Key Companies at the Horizon Expected to Transform the Treatment...
Kura Oncology Logo
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
May 07, 2019 16:05 ET | Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA...
Kura Oncology Logo
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
October 22, 2018 08:45 ET | Kura Oncology, Inc.
– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC...
Kura Oncology Logo
Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
September 26, 2018 16:05 ET | Kura Oncology, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology to Present at H.C. Wainwright Global Investment Conference
August 30, 2018 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
August 07, 2018 16:05 ET | Kura Oncology, Inc.
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 06, 2018 16:05 ET | Kura Oncology, Inc.
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming...
Kura Oncology Logo
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
June 28, 2018 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
June 20, 2018 07:30 ET | Kura Oncology, Inc.
– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
Kura Oncology Logo
Kura Oncology to Present at JMP Securities Life Sciences Conference
June 14, 2018 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...